Generic Temodar Launched by Mylan

Mylan has launched a generic version of Merck's Temodar capsules, which may be used to treat patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy, then as maintenance treatment.

Mylan has launched a generic version of Merck’s Temodar capsules, which may be used to treat patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy, then as maintenance treatment.

Mylan’s temozolomide capsules will come in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg dosage forms. The manufacturer announced the approval of its abbreviated new drug application on July 11, 2016.

The capsules had US sales of $176.5 million in the 12 months ending May 31, 2016, according to IMS Health.

The most common adverse reactions associated with Temodar are fatigue, headache, nausea, and vomiting. Allergic reactions have also been reported in some patients.

Temodar is not recommended for pregnant women, as it may cause fetal harm. At the moment, it is not known if Temodar may impact nursing mothers. Additionally, the drug has not been researched for use in pediatric patients.